{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(4)"],"submitter":["Poletto F"],"pubmed_abstract":["<b>Background</b>: Therapeutic/intermediate-dose heparin reduces the risk of thromboembolic events but increases the risk of major bleeding in patients hospitalized for acute COVID-19 pneumonia. <b>Objectives</b>: To prospectively assess the incidence of objectively proven venous thromboembolism (VTE) and identify predisposing risk factors in a cohort of hospitalized patients with acute COVID-19 pneumonia undergoing prophylactic-dose heparin. <b>Patients and methods</b>: All consecutive patients admitted for acute COVID-19 pneumonia to the General Internal Medicine Unit of Padova University Hospital, Italy between November 2020 and April 2021, and undergoing prophylactic-dose heparin, were enrolled. Demographic and clinical characteristics and laboratory and radiological findings were reco"],"journal":["Viruses"],"pagination":["737"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9025628"],"repository":["biostudies-literature"],"pubmed_title":["Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation."],"pmcid":["PMC9025628"],"pubmed_authors":["Poletto F","Spiezia L","Simioni P","Tormene D","Camporese G","Campello E","Dalla Valle F","Simion C"],"additional_accession":[]},"is_claimable":false,"name":"Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation.","description":"<b>Background</b>: Therapeutic/intermediate-dose heparin reduces the risk of thromboembolic events but increases the risk of major bleeding in patients hospitalized for acute COVID-19 pneumonia. <b>Objectives</b>: To prospectively assess the incidence of objectively proven venous thromboembolism (VTE) and identify predisposing risk factors in a cohort of hospitalized patients with acute COVID-19 pneumonia undergoing prophylactic-dose heparin. <b>Patients and methods</b>: All consecutive patients admitted for acute COVID-19 pneumonia to the General Internal Medicine Unit of Padova University Hospital, Italy between November 2020 and April 2021, and undergoing prophylactic-dose heparin, were enrolled. Demographic and clinical characteristics and laboratory and radiological findings were reco","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-29T10:58:03.823Z","creation":"2025-02-19T00:47:24.157Z"},"accession":"S-EPMC9025628","cross_references":{"pubmed":["35458467"],"doi":["10.3390/v14040737"]}}